NIH Countermeasures Against Chemical Threats (CounterACT) Program Cooperative Agreement (UG3/ UH3) Q&A Webinar

July 27, 2022 | 1:00 - 2:00 PM

The Countermeasures Against Chemical Threats (CounterACT) Program is a trans-NIH initiative that supports research and development of new and improved therapeutics against chemical threat agents. The CounterACT Program is pleased to host a webinar in which they will discuss a new Cooperative Agreement funding mechanism. Attendees are encouraged to attend to learn more about research supported by the NIH CounterACT program and this new flagship opportunity, in particular.

PAR-22-209 CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)

This is a Funding Opportunity Announcement (FOA) that solicits applications for the early-stage development of therapeutics to mitigate the adverse health effects resulting from toxic chemical exposure. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include specific chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. The overall scope of this solicitation includes validation of therapeutic targets and preclinical characterization of lead compounds. The UG3 phase of this FOA supports target validation and characterization of initial lead compound(s); UH3 phase activities include candidate optimization and in vivo demonstration of activity and efficacy in relevant post-exposure models. At the conclusion of the overall UG3/UH3 funding period, projects are expected to deliver at least one well-characterized therapeutic candidate.

For further information, please contact Dr. Neel Dhruv.

Webinar Slides(pdf, 2432 KB)